Your new post is loading...
A biotherapeutic company that fully powers the antibody-drug conjugate development spectrum from a patient-based approach to target and functional antibody discovery to ADC creation and manufacturing, accelerating development and the delivery of effective therapies to patients.
In recent years, ADCs have become an important tool in fighting cancer. Our rigorous approach to target discovery and antibody development considers patient profile, tissue expression, tumor environment and antibody function as primary factors. Our target discovery platform, sTAg, systematically profiles proteins found on the cell surface of primary tumors to identify antibody-accessible antigens as candidate targets. Tumor-specific surface proteins are identified and quantified by applying advanced mass spectrometry analysis. To identify functional antibodies that are specific to target candidates, we have developed a platform, iTAb, that screens Ab candidates in vivo, to select antibodies with the most potent anti-tumor response.
Via Krishan Maggon
Ingenica proprietary site-specific ADC platform technology, SNAP, addresses the major limitations of current and competitive approaches by providing a simple, elegant, chemically-driven method for linking a functional Ab and small molecule cytotoxin. Our SNAP technology results in a highly flexible bi-functional linker that, by design, yields homogeneous ADCs armed with the optimal toxin payload. SNAP is also a highly flexible system that is amenable to any antibody, linker or toxin, making it an ideal technology for internally and externally generated programs.